ACOR Share Price

Open 21.25 Change Price %
High 21.45 1 Day -0.90 -4.21
Low 20.40 1 Week -0.25 -1.20
Close 20.50 1 Month 0.40 1.99
Volume 460499 1 Year -19.40 -48.62
52 Week High 40.57
52 Week Low 16.40
ACOR Important Levels
Resistance 2 21.47
Resistance 1 21.07
Pivot 20.78
Support 1 19.93
Support 2 19.53
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
AAPL 119.97 0.78%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
AMCF 0.06 50.00%
LOCM 0.09 50.00%
REXX 0.74 42.31%
CWEI 145.25 39.69%
CLSN 0.51 30.77%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HTCO 4.95 22.83%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LLEN 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Acorda Therapeutics, Inc. (NASDAQ: ACOR)

ACOR Technical Analysis 2
As on 17th Jan 2017 ACOR Share Price closed @ 20.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 24.85 & Buy for SHORT-TERM with Stoploss of 19.92 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACOR Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ACOR Other Details
Segment EQ
Market Capital 995115008.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.acorda.com
ACOR Address
ACOR
420 Saw Mill River Road
Ardsley, NY 10502
United States
Phone: 914-347-4300
Fax: 914-347-4560
Interactive Technical Analysis Chart Acorda Therapeutics, Inc. ( ACOR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Acorda Therapeutics, Inc.
ACOR Business Profile
Acorda Therapeutics, Inc. (Acorda), incorporated on March 17, 1995, is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). It also sells Zanaflex Capsules and Zanaflex tablets, which contain tizanidine hydrochloride, a short-acting drug for the management of spasticity. Ampyra is marketed as Fampyra outside the United States by Biogen Idec International GmbH (Biogen Idec). On February 6, 2012, the Company launched tizanidine hydrochloride capsules, an authorized generic version of Zanaflex Capsules under an agreement with Watson Pharma, Inc. In December 2012, the Company acquired Neuronex, Inc.